Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Msn Laboratories Private Limited R&D Center currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is handled by 1 distinct examiner, CHANDRAKUMAR, NIZAL S, who is the busiest examiner for the portfolio with 1 pending matter. All prosecution activity is located within 1 distinct art unit. This centralized structure means that the company's current patent strategy is focused on a single examiner and administrative unit.
For a practitioner, having 1 pending office action assigned to 1 distinct examiner within 1 distinct art unit creates a highly focused prosecution environment. This concentration means that the success of the current portfolio depends entirely on the relationship with CHANDRAKUMAR, NIZAL S. While this simplifies the management of the portfolio, it also means there is no diversification of examiner perspectives. Strategic efforts should be directed toward understanding the specific examination history of this single examiner to optimize the chances of allowance for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252882 | NOVEL PROCESS FOR THE PREPARATION OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE OR ITS SALTS THEREOF | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252882 | NOVEL PROCESS FOR THE PREPARATION OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE OR ITS SALTS THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | — | Pending | May 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMsn Laboratories Private Limited R&D Center has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Msn Laboratories Private Limited R&D Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.